Is there a hypercoagulable phase during initiation of antithrombotic therapy with oral anticoagulants in patients with atrial fibrillation?

Thrombosis Research

Volumn 109, Issue 5-6, 2003, Pages 241-246

  Zeuthen, Elisabeth L ^a   Lassen, Jens F ^a   Husted, Steen E ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Anticoagulation; Atrial fibrillation; Biochemical markers; Low molecular weight heparin

Indexed keywords

ANTICOAGULANT AGENT; BIOCHEMICAL MARKER; D DIMER; FIBRIN; LOW MOLECULAR WEIGHT HEPARIN; PROTHROMBIN; WARFARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERCOAGULABILITY; LABORATORY TEST; MALE; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0038345858     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(03)00240-8     Document Type: Article

References (15)

1. Wolf P.A., Abbott R.D., Kannel W.B. Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. Arch. Intern. Med. 147:1987;1561-1564.
2. Mitusch R., Siemens H.J., Garbe M., Wagner T., Sheikhzadeh A., Diederich K.W. Detection of a hypercoagulable state in nonvalvular atrial fibrillation and the effect of anticoagulant therapy. Thromb. Haemos. 75(2):1996;219-223.
3. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch. Intern. Med. 154:1994;1449-1457.
4. Asakura H., Hifumi S., Jokaji H., Saito M., Kumabashiri I., Uotani C.et al. Prothrombin fragment F1+2 and thrombin-antithrombin III complex are useful markers of the hypercoagulable state in atrial fibrillation. Blood Coagul. Fibrinolysis. 3:1992;469-473.
5. Lip G.Y.H., Lip P.L., Zarifis J., Watson R.D.S., Bareford D., Lowe G.D.O.et al. Fibrin D-dimer and b thromboglobulin as markers of thrombogenesis and platelet activation in atrial fibrillation. Effects of introducing ultra low-dose warfarin and aspirin. Circulation. 94:1996;425-431.
6. Lip G.Y.H., Lowe G.D.O., Rumley A., Dunn F.G. Increased markers of thrombogenesis in chronic atrial fibrillation: effects of warfarin treatment. Br. Heart J. 73:1995;527-533.
7. Hirsh J. Mechanism of action and monitoring of anticoagulants. Semin. Thromb. Hemost. 12(1):1986;1-11.
8. Stirling Y. Warfarin-induced changes in procoagulant and anticoagulant proteins. Review paper. Blood Coagul. Fibrinolysis. 6:1995;361-373.
9. Harrison L., Johnston M., Massicotte M.P., Crowther M.A., Moffat K., Hirsh J. Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. [see comments] Ann. Intern. Med. 126:1997;133-136.
10. Bruhn H.D., Liebsch J., Wagner C. Documentation of hypercoagulability by measurement of prothrombin fragment F1+2 when introducing oral anticoagulant therapy. Thromb. Res. 68:1992;317-319.
11. Teitel J.M., Bauer K.A., Lau H.K., Rosenberg R.D. Studies of the prothrombin activation pathway utilizing radioimmunoassay for the F2/F1+2 fragment and thrombin-antithrombin complex. Blood. 59(5):1982;1086-1097.
12. Lip G.Y.H., Lowe G.D.O. Fibrin D-dimer: a useful marker of thrombogenesis. Clin. Sci. 89:1995;205-214.
13. Nieuwenhuizen W. Soluble fibrin as a molecular marker for a pre-thrombotic state: a mini-review. Blood Coagul. Fibrinolysis. 4:1993;93-96.
14. Crowther M.A., Ginsberg J.B., Kearon C., Harrison L., Johnson J., Massicotte M.P.et al. A randomized trial comparing 5-mg and 10-mg warfarin loading doses. [see comments] Arch. Intern. Med. 159:1999;46-48.
15. Peternel P., Terbizan M., Tratar G., Bozic M., Horvat D., Salobir B.et al. Markers of hemostatic system activation during treatment of deep vein thrombosis with subcutaneous unfractionated or low-molecular weight heparin. Thromb. Res. 105(3):2002;241-246.